These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21195307)

  • 41. Clinical trials referral resource. Current clinical trials in multiple myeloma.
    Davis T; Schoenfeldt M
    Oncology (Williston Park); 2004 Feb; 18(2):196-8, 203. PubMed ID: 15008057
    [No Abstract]   [Full Text] [Related]  

  • 42. [Multiple myeloma; treatment in the year 1998].
    Lokhorst HM; Sonneveld P; Wijermans PW; Segeren CM
    Ned Tijdschr Geneeskd; 1998 Jul; 142(28):1596-602. PubMed ID: 9763840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conventional therapy and approach to management.
    Rajkumar SV; Kyle RA
    Best Pract Res Clin Haematol; 2005; 18(4):585-601. PubMed ID: 16026739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of high-dose therapy with autologous stem cell support in the era of novel agents.
    Attal M; Harousseau JL
    Semin Hematol; 2009 Apr; 46(2):127-32. PubMed ID: 19389496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Standard therapy for multiple myeloma].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2012 Oct; 53(10):1675-88. PubMed ID: 23037740
    [No Abstract]   [Full Text] [Related]  

  • 47. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
    Bladé J; Samson D; Reece D; Apperley J; Björkstrand B; Gahrton G; Gertz M; Giralt S; Jagannath S; Vesole D
    Br J Haematol; 1998 Sep; 102(5):1115-23. PubMed ID: 9753033
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase 3 trials suggest ways to improve current hematologic cancer therapies.
    Hampton T
    JAMA; 2008 Feb; 299(5):510-2. PubMed ID: 18252877
    [No Abstract]   [Full Text] [Related]  

  • 49. [Multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2013 Jan; 54(1):89-99. PubMed ID: 23391652
    [No Abstract]   [Full Text] [Related]  

  • 50. A new co-operative group: the European Myeloma Network Trialist Group.
    Leuk Lymphoma; 2009 Oct; 50(10):1581-8. PubMed ID: 19757308
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase III clinical trials in oncology. 20-21 January 2003, London, UK.
    Buyse M
    IDrugs; 2003 Mar; 6(3):187-90. PubMed ID: 12838977
    [No Abstract]   [Full Text] [Related]  

  • 52. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VI. Standard Treatment for Multiple Myeloma].
    Ito S; Takano M
    Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1238-45. PubMed ID: 30168968
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of multiple myeloma: whence truth over belief?
    Kaufman J; Lonial S
    Oncology (Williston Park); 2009 Apr; 23(5):420, 423. PubMed ID: 19476275
    [No Abstract]   [Full Text] [Related]  

  • 54. [XIth International myeloma workshop, 2007, June 25-30, Kos island, Greece].
    Decaux O
    Rev Med Interne; 2008 May; 29(5):439-40. PubMed ID: 18394760
    [No Abstract]   [Full Text] [Related]  

  • 55. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
    Rajkumar SV; Harousseau JL; Durie B; Anderson KC; Dimopoulos M; Kyle R; Blade J; Richardson P; Orlowski R; Siegel D; Jagannath S; Facon T; Avet-Loiseau H; Lonial S; Palumbo A; Zonder J; Ludwig H; Vesole D; Sezer O; Munshi NC; San Miguel J;
    Blood; 2011 May; 117(18):4691-5. PubMed ID: 21292775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are we doing the right phase III trials?
    Burton A
    Lancet Oncol; 2007 Mar; 8(3):193. PubMed ID: 17348107
    [No Abstract]   [Full Text] [Related]  

  • 57. The research mission in myeloma.
    Richardson PG; San-Miguel J; Lonial S; Reece D; Jakubowiak A; Hussein M; Jagannath S; Mitsiades CS; Raje N; Kaufman J; Avigan D; Ghobrial I; Schlossman RL; Munshi N; Dalton W; Anderson KC
    Leukemia; 2009 Feb; 23(2):422-3; author reply 423-4. PubMed ID: 18685616
    [No Abstract]   [Full Text] [Related]  

  • 58. Terminated microbicide trial to be investigated.
    Future Microbiol; 2007 Apr; 2(2):103. PubMed ID: 17661647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. III. AB-100 (NSC-37095).
    BROWN CL; BERGSAGEL DE; LEVIN WC
    Cancer Chemother Rep; 1962 Aug; 21():81-5. PubMed ID: 13873596
    [No Abstract]   [Full Text] [Related]  

  • 60. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.
    Klausen TW; Gregersen H; Abildgaard N; Andersen NF; Frølund UC; Gimsing P; Helleberg C; Vangsted AJ
    Leukemia; 2019 Feb; 33(2):546-549. PubMed ID: 30267010
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.